Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination of a probiotic bacterial strain, bifidobacterium animalis lactis VES002, and fructo-oligosaccharides (FOS), a type of prebiotic.** Bifidobacterium animalis lactis VES002 is a proprietary probiotic strain used to help maintain or restore healthy intestinal microflora, particularly **intestinal barrier integrity and mucosal immunity**. It acts primarily through modulation of the gut microbiome, enhancement of IgA secretion, and restoration of tight junction proteins, potentially via activation of Toll-like receptor 2 (TLR2) pathways. Fructooligosaccharides function as prebiotics, selectively stimulating the growth of beneficial gut bacteria such as bifidobacteria and lactobacilli. This combination is typically formulated as a dietary supplement to improve or support digestive health and immune modulation in humans, particularly in cases of intestinal dysbiosis, antibiotic use, or compromised gut barrier[1][3][4]. Developers often conduct strain-specific research, so the VES002 designation suggests a proprietary variant, distinct from common reference strains such as BB-12 or HY8002. While there is robust evidence for combinations of Bifidobacterium animalis lactis strains and FOS, explicit published data on VES002 is limited; the product's expected effects and mechanisms are inferred from related strains[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bifidobacterium animalis lactis VES002 + fructo-oligosaccharides.